Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/115127
Título: | Principles in the Management of Glioblastoma | Autor: | Roda, Domingos Veiga, Pedro Melo, Joana Barbosa Carreira, Isabel Marques Ribeiro, Ilda Patrícia |
Palavras-chave: | genetic and epigenetic biomarkers; glioblastoma; liquid biopsies; mutations; signaling pathways; target therapies | Data: | 17-Abr-2024 | Editora: | MDPI | Título da revista, periódico, livro ou evento: | Genes | Volume: | 15 | Número: | 4 | Resumo: | Glioblastoma, the most aggressive and common malignant primary brain tumour, is characterized by infiltrative growth, abundant vascularization, and aggressive clinical evolution. Patients with glioblastoma often face poor prognoses, with a median survival of approximately 15 months. Technological progress and the subsequent improvement in understanding the pathophysiology of these tumours have not translated into significant achievements in therapies or survival outcomes for patients. Progress in molecular profiling has yielded new omics data for a more refined classification of glioblastoma. Several typical genetic and epigenetic alterations in glioblastoma include mutations in genes regulating receptor tyrosine kinase (RTK)/rat sarcoma (RAS)/phosphoinositide 3-kinase (PI3K), p53, and retinoblastoma protein (RB) signalling, as well as mutation of isocitrate dehydrogenase (IDH), methylation of O6-methylguanine-DNA methyltransferase (MGMT), amplification of epidermal growth factor receptor vIII, and codeletion of 1p/19q. Certain microRNAs, such as miR-10b and miR-21, have also been identified as prognostic biomarkers. Effective treatment options for glioblastoma are limited. Surgery, radiotherapy, and alkylating agent chemotherapy remain the primary pillars of treatment. Only promoter methylation of the gene MGMT predicts the benefit from alkylating chemotherapy with temozolomide and it guides the choice of first-line treatment in elderly patients. Several targeted strategies based on tumour-intrinsic dominant signalling pathways and antigenic tumour profiles are under investigation in clinical trials. This review explores the potential genetic and epigenetic biomarkers that could be deployed as analytical tools in the diagnosis and prognostication of glioblastoma. Recent clinical advancements in treating glioblastoma are also discussed, along with the potential of liquid biopsies to advance personalized medicine in the field of glioblastoma, highlighting the challenges and promises for the future. | URI: | https://hdl.handle.net/10316/115127 | ISSN: | 2073-4425 | DOI: | 10.3390/genes15040501 | Direitos: | openAccess |
Aparece nas coleções: | I&D CIBB - Artigos em Revistas Internacionais FMUC Medicina - Artigos em Revistas Internacionais I&D ICBR - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
genes-15-00501 (1).pdf | 3.46 MB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
4
Visto em 23/set/2024
Citações WEB OF SCIENCETM
2
Visto em 2/set/2024
Visualizações de página
140
Visto em 25/set/2024
Downloads
45
Visto em 25/set/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons